Searched for
ONBREZ
Cipla, Novartis explore marketing tie-upCipla lost its battle with Novartis in March, when the Delhi High Court stayed the company’s request to sell copies of Novartis respiratory...- Delhi High Court quashes Cipla's appeal, says it can't market generics of Novartis' OnbrezThe court said it can't make a definitive conclusion that Novartis' imports of Onbrez were insufficient to meet the demands COPD patients f...
- Delhi High Court upholds ruling barring Cipla from selling copies of Novartis drugAccording to the judgment, Cipla had claimed that 10 tablets of Onbrez cost Rs 677 as opposed to its own drug priced at Rs 130.
- Novartis India shares jump over 17% on buyback planThe company’s shares closed at Rs 833 on the Bombay Stock Exchange. On May 18, the company had announced it would hold its board meeting on...
- Lupin to market Novartis' inhaler under Loftair brand nameAccording to IMS sales data, Lupin is ranked second with 12.4 per cent market share of the overall anti-asthma segment within the Indian ph...
- Onbrez case: Delhi High Court reserves decision on Novartis-Cipla patent disputeDelhi High Court has reserved its decision on a high-profile patent case that pitted Swiss drug maker Novartis against Cipla over its respi...
- Pharma MNCs like Johnson & Johnson, Novartis, step up India play with star drug launchesIn fact, pharma MNCs in India are growing faster than their local counterparts: according to AIOCD data, they expanded 13.8 per cent in Jul...
- Delhi High Court notice to Novartis on Cipla plea"We will not give you an interim order. We will hear it on an early date and dispose it of. Notice. Renotify on February 5," the bench said.
- Cipla moves Delhi High Court against restraint on its Indacaterol-based drugThe matter was mentioned before a bench of Justices Badar Durrez Ahmed and Sanjeev Sachdeva who directed that the plea be listed before the...
- High Court stops Cipla's generic drug salesSources said the court on Friday issued an interim injunction directing Cipla to stop the sale of the generic drug in the market.
- Delhi High Court restrains Cipla from selling drug containing IndacaterolHC temporarily restrained Cipla from manufacturing, importing or selling any drug containing the chemical Indacaterol.
- Ten stocks in focus in Thursday morning tradeIndian markets are expected to trade higher. Here is a list of ten stocks which are likely to be in focus today.
- HC reserves order on Novartis-Cipla drug disputeThe Delhi High Court has reserved its verdict on a dispute between pharma firms Novartis and Cipla over manufacturing of the drug Indacater...
- Government may not act on Cipla’s patent pleaCipla's proposal for the medicines under section 92 of the Patents Act may not be "fit" to pass legal scrutiny- Health ministry
- MNCs deprive India of vital drugs despite getting monopoly rightsJapanese firm Otsuka Pharmaceuticals, Myers-Squibb, Novartis are deferring launch of medicines critical for treatment of serious non-commun...
- Cipla-Novartis patent row: DIPP looking into merit of caseNovartis merely imports a negligible quantity of these products manufactured in Switzerland as per its own data filed before the Patent off...
- Cipla asks government to revoke Novartis' patent; launches its drugCipla has launched low-cost generic version of Novartis's respiratory drug Indacaterol while asking government to revoke patents over the m...
- Cipla asks government to revoke five patents held by NovartisCipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug O...
- Fifteen stocks in focus in Thursday morning tradeIndian markets are expected to trade in a range. Here is a list of fifteen stocks which are likely to be in focus today.
- Novartis India vice-chairman & managing director, Ranjit Shahani says company now focuses on new products, business growthNovartis India has over the past year launched three successful patented drugs and over 12 generic drugs that have helped it expand its pre...
Load More
